Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. Fu, B. Zhou, D. Ren, M. Chen, X. Jie, Y. Wang, J. Xu (Guangzhou, China). An extract from a traditional Chinese medicine polyherbal formula and its main active ingredients regulate cAMP signaling: A potential treatment for lung fibrosis. Eur Respir J 2012; 40: Suppl. 56, 3763

Member's Comments

No comment yet.

Related content which might interest you: Japanese herbal medicine Hochu-ekki-to (TJ-41) attenuates lung inflammation in lung emphysema. Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 The role of monoterpenes derived from essential oils in lung alteration in a model of emphysema Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Bufei Yishen granules and it combined with acupoint sticking therapy suppresses inflammation in COPD rats: via JNK/p38 signaling pathway Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia Year: 2017 Anti-tumor activities by a ginsenoside Rg3 formulation prepared from Korean ginseng in mouse lung cancer model Source: Eur Respir J 2007; 30: Suppl. 51, 468s Year: 2007 Astragalus membranaceus, a traditional Chinese medicine, enhances T-helper cell type I polarization and interferon-gamma production by increasing T-bet expression in asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006 A novel mucoactive herbal drug, radix ophiopogonis Source: Eur Respir J 2002; 20: Suppl. 38, 283s Year: 2002 A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators Source: Eur Respir Rev, 27 (148) 170124; 10.1183/16000617.0124-2017 Year: 2018 SERCA2a gene therapy ameliorates pulmonary hypertension in a pig model: comparison of different delivery methods and therapeutic effect Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 ß-Escin and chokeberry extract diet supplementation in healthy smokers as potential anti- inflammatory and antioxidant protection – a pilot study. Source: Virtual Congress 2020 – Smoking disease landscape: from inflammation to lung function and comorbidities Year: 2020 Astragalus membranaceus promotes the function of regulatory t cells from asthma patients in remission periods in vitro Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 A combination of thyme and primula dry extracts possesses antitussive activity and inhibits leukotriene formation Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Anticancer and cancer prevention effects of toona sinensis leaf extract in human NSCLC cell Source: Eur Respir J 2006; 28: Suppl. 50, 388s Year: 2006 Herbal medicines for the treatment of COPD: a systematic review Source: Eur Respir J 2006; 28: 330-338 Year: 2006 Oral presentation: NF-?? acts downstream of EGFR in regulating low dose cadmium induced primary lung cell proliferation Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013 Inhibition of phosphodiesterase 4B enhances glucocorticoid-dependent gene transcription in human airway epithelial cells: Implications for the treatment of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 The inhibitory effect of fenretinide on the expression of inflammatory cytokines, possible molecular target of the drug and its relevance to cystic fibrosis. Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy Source: Breathe, 17 (4) 210112; 10.1183/20734735.0112-2021 Year: 2021